Before Invest
ABBOTT LABORATORIES logo

ABBOTT LABORATORIES

ABT
Pharmaceutical Preparations
Last filing · Quarter 2 · Jun 30, 2026
Financial Statements Ratios
Export XLSX
Statement
Income StatementBalance Sheet
Period
Annual Quarterly
Order
Unlock 14 years
Format
% Change
Rows
USD ($)
$ in Millions 		Dec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016Dec 31, 2015Dec 31, 2014Dec 31, 2013Dec 31, 2012Dec 31, 2011Dec 31, 2010Dec 31, 2009
Current assets:
                 
Cash and cash equivalents
$ 8,522
$ 7,616
$ 6,896
Investments, primarily bank time deposits and U.S. treasury bills
417
351
383
Restricted funds, primarily U.S. treasury bills
-
-
-
Trade receivables, less allowances of — 2025: $490; 2024: $439
7,929
6,925
6,565
Inventories:
                 
Finished products
3,976
3,700
3,946
Work in process
904
840
807
Materials
1,608
1,654
1,817
Total inventories
6,488
6,194
6,570
Other prepaid expenses and receivables
2,640
2,570
2,256
Deferred income taxes
-
-
-
Current assets held for disposition
-
-
-
Total current assets
25,996
23,656
22,670
Investments
918
886
799
Property and equipment, at cost:
                 
Land
541
528
529
Buildings
4,543
4,207
4,161
Equipment
17,571
15,517
15,179
Construction in progress
2,567
2,488
2,064
Property and equipment, at cost
25,222
22,740
21,933
Less: accumulated depreciation and amortization
13,406
12,082
11,779
Net property and equipment
11,816
10,658
10,154
Intangible assets, net of amortization
5,526
6,647
8,815
Goodwill
24,035
23,108
23,679
Deferred income taxes and other assets
18,422
16,459
7,097
Non-current Assets Held for Disposition
-
-
-
Total Assets
86,713
81,414
73,214
Liabilities and Shareholders’ Investment
                 
Current liabilities:
                 
Short-term borrowings
-
-
-
Trade accounts payable
4,240
4,195
4,295
Salaries, wages, and commissions
1,745
1,701
1,597
Other accrued liabilities
5,812
5,143
5,422
Dividends payable
1,097
1,024
955
Income taxes payable
569
594
492
Current portion of long-term debt
3,033
1,500
1,080
Current liabilities held for disposition
-
-
-
Total current liabilities
16,496
14,157
13,841
Long-term debt
9,896
12,625
13,599
Post-employment obligations and other long-term liabilities
7,550
6,731
6,947
Non-current liabilities held for disposition
-
-
-
Shareholders’ investment:
                 
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued
0
0
0
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2025: 1,996,795,525; 2024: 1,991,472,630
25,527
25,153
24,869
Common shares held in treasury, at cost — Shares: 2025: 260,196,074; 2024: 259,774,639
17,177
16,844
15,981
Earnings employed in the business
49,781
47,261
37,554
Accumulated other comprehensive income (loss)
(6,001)
(7,906)
(7,839)
Total Abbott Shareholders’ Investment
52,130
47,664
38,603
Noncontrolling interests in subsidiaries
641
237
224
Total Shareholders’ Investment
52,771
47,901
38,827
Total Liabilities and Shareholders' Investment
$ 86,713
$ 81,414
$ 73,214